原始出處紀錄

pembrolizumab · NCT06295731 登記更新

狀態：ACTIVE_NOT_RECRUITING → RECRUITING；主要完成：2029-05 → 2029-12；完成：2029-05 → 2031-05；登記人數：410 → 450；主要結果：['Phase 2: Objective Response Rate (ORR)', 'Phase 3: Progression-Free Survival (PFS)', 'Phase 3: Overall Survival (OS)'] → ['Phase 2: Objective Response Rate by investigator (ORRinv)', 'Phase 3: Progression-Free Survival by Investigator (PFSinv)', 'Phase 3: Overall Survival (OS)']；國家：{'total_sites': 87, 'us_sites': 25} → {'total_sites': 89, 'us_sites': 26}